Moomoo AI 已提取核心信息
On February 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, executed a sale of company stock. The transaction involved the disposal of 20,000 common shares at prices ranging from $79.9359 to $81.6645 per share, resulting in a total market value of $1,607,177.46. Prior to the sale, Kulkarni acquired the same number of shares through the exercise of derivative securities at a price of $19.12 per share. Following the transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an entity not directly tied to the reported transactions.
On February 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, executed a sale of company stock. The transaction involved the disposal of 20,000 common shares at prices ranging from $79.9359 to $81.6645 per share, resulting in a total market value of $1,607,177.46. Prior to the sale, Kulkarni acquired the same number of shares through the exercise of derivative securities at a price of $19.12 per share. Following the transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an entity not directly tied to the reported transactions.
2024年2月15日，CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼执行了公司股票的出售。该交易涉及以每股79.9359美元至81.6645美元的价格出售20,000股普通股，总市值为1,607,177.46美元。出售之前，库尔卡尼通过行使衍生证券以每股19.12美元的价格收购了相同数量的股票。交易完成后，库尔卡尼在CRISPR Therapeutics的直接持股量为187,377股。此外，库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权，该实体与报告的交易没有直接关系。
2024年2月15日，CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼执行了公司股票的出售。该交易涉及以每股79.9359美元至81.6645美元的价格出售20,000股普通股，总市值为1,607,177.46美元。出售之前，库尔卡尼通过行使衍生证券以每股19.12美元的价格收购了相同数量的股票。交易完成后，库尔卡尼在CRISPR Therapeutics的直接持股量为187,377股。此外，库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权，该实体与报告的交易没有直接关系。
有用
没用